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Zonisamide for Migraine Prophylaxis in Refractory Patients
Avi Ashkenazi, M.D., Adam Benlifer, B.S., Jason Korenblit, B.S.,
Stephen D. Silberstein, M.D., F.A.C.P
Jefferson Headache Center
Philadelphia, PA

Zonisamide, a new antiepileptic drug, has been approved in the US as adjunctive therapy
for the treatment of partial seizures in adults.1,2 Chemically a sulfonamide analogue,
zonisamide is thought to have several mechanisms of action, including a rate-dependent
blockade of voltage-gated sodium channels and reduction of ion flow through T-type
calcium channels.3-5 It is also a weak carbonic anhydrase inhibitor. Zonisamide has a
favorable pharmacokinetic profile that includes high oral bioavailability and a long half
life (63 hours), permitting a once- or twice-daily dosing regimen.6
There are only a limited number of current migraine preventive medications that have
proven efficacy. Their use is often limited because of adverse events (AEs) in a
significant number of patients.7 Because of its pharmacologic properties, zonisamide is
potentially an effective drug for migraine prevention, and preliminary data suggest that it
may be effective for this indication.8-10 The long half life of the drug makes it a good
candidate for migraine patients who have poor compliance to preventive therapy that
involves multiple daily dosing.
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The aim of this study was to evaluate the efficacy and tolerability of zonisamide for
migraine prophylaxis in refractory patients attending a tertiary headache center.

Methods:
The study was approved by the Jefferson University Hospital Institutional Review Board.
We reviewed the charts of adult patients (18 years of age or older) who had a diagnosis of
episodic migraine (EM) with or without aura, as defined by the International Headache
Society (IHS), or with transformed migraine (TM) according to the Silberstein-Lipton
criteria.11,12 Included patients had been treated with zonisamide at the Jefferson
Headache Center from January 2001 to June 2003 for a minimum of 60 days.
Demographic data, including weight, zonisamide dosage and duration of treatment, were
collected and analyzed. History of patients’ previous migraine treatments and their
outcome was analyzed. The following disease-related parameters were evaluated: number
of headache days per month, average headache severity (measured using an 11-point
verbal scale), average headache attack duration, and headache-associated disability, as
measured by the number of missed days from school/work per month. Data on these
parameters before initiation of zonisamide treatment and at the last office visit after
treatment initiation were abstracted and compared. The type, severity, and prevalence of
AEs were abstracted.
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Statistical analysis:
We used paired t-test to compare the value of each parameter before the initiation of
zonisamide treatment to the corresponding value at the last follow-up after treatment
initiation. The level of significance was set at p<0.05.

Results:
Thirty-three patients (27 women and six men) were included in the study. Their average
age was 43.9±8.4 years (range: 20-61 years). Twenty-three (70%) had transformed
migraine and 10 (30%) had episodic migraine. The average duration of disease was
23.8±12.1 years (range: 2-51 years). Twenty four patients (72%) had psychiatric comorbidity, including depression (15 patients), anxiety (four patients), adjustment disorder
(four patients) and bipolar disorder (two patients). The patients had failed an average of
6.2 migraine prophylactic drugs prior to zonisamide. The headache-preventive
medication class most commonly used prior to zonisamide therapy was anticonvulsants
(30 patients, 91%), followed by antidepressants (22 patients, 66%), herbal medications,
vitamins and minerals (18 patients, 54%) and anti-psychotic drugs (16 patients, 48%)
(Table). Seventeen patients were on zonisamide alone and sixteen were on polytherapy
(i.e. on zonisamide and at least one other migraine preventive drug). The patients used a
variety of acute pain medications during the study evaluation period, including triptans,
NSAIDs, neuroleptics, and, rarely, opioids. In accordance with our clinical practice, the
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use of these medications was limited to no more than three days per week total, and no
more than two days/week for triptans and opioids.
Zonisamide treatment was started at a dose of 100 mg/day and, in the majority of patients
(18/33, 55%) was titrated up by 100 mg/day every week to an initial target dose of 300
mg/day. In 12 (36%) patients, the rate of zonisamide titration was slower, and in 3 (9%)
it was more rapid. In 16 (48%) patients, the zonisamide dose was increased above 300
mg/day, up to a maximum of 600 mg/day, in an attempt to achieve headache control,
while 9 (27%) patients remained on less than 300 mg/day because of decreased tolerance.
The average zonisamide daily dose was 337.9±146.3 mg (range: 100-600 mg). The
average total duration of treatment was 186.4±174.0 days (range: 61-780 days), and the
average duration of treatment on the maximal maintenance dose of zonisamide was
159±210 days.

The average number of days with headache per month was reduced from 20.7±9.5 before
the initiation of zonisamide treatment to 18.0±11.3 after treatment initiation (p=0.06)
(figure). The corresponding median values were 24 and 18 days. Data stratification
showed that the number of days with headache per month was reduced from 24.7±7.3
before initiation of zonisamide treatment to 21.0±10.7 after treatment initiation in
patients with TM (p=0.06). The corresponding values for patients with EM were 11.6±7.6
and 11.0±9.7 (p=n/s) (figure). No significant changes in headache severity, headache
duration, or the number of missed days from school or work occurred after zonisamide
treatment was initiated.
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Fourteen patients (42.4%) reported AEs, the most common of which was fatigue (4
patients, 12%). Other AEs included irritability, anxiety, concentration difficulties,
dizziness, gastrointestinal upset, foot edema, and renal calculi. Most patients (12/14,
85.7%) rated AEs as mild or moderate. There was no significant change in weight with
zonisamide therapy (the average weight before treatment initiation was 80.0 ±25.5 kg vs.
80.9±25.9 kg at the last office visit after treatment initiation).

Discussion:
In this retrospective study of refractory migraine patients, zonisamide treatment was
associated with a small, non-statistically significant, decrease in the number of headache
days per month.There was no significant effect of zonisamide on any of the other
headache parameters. Interestingly, the mild beneficial effect of zonisamide was seen in
TM, but not in EM, patients.

Other studies have suggested that zonisamide may be effective in migraine prevention.
Drake et al. conducted an open label study to examine the effect of zonisamide on
headache in 34 refractory migraine patients.8 Zonisamide treatment was initiated at a
dose of 100 mg/day and titrated up to 400 mg/day as tolerated. Significant improvement
in headache frequency, severity, and duration was evident one month after initiation of
zonisamide therapy, which continued throughout the three-month study period.
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Zonisamide was well-tolerated. Smith conducted an open label study to evaluate the
efficacy of zonisamide, given at a dose of 100-200 mg/day, on 16 patients with refractory
chronic daily headache.9 Three months after initiation of zonisamide treatment, both
average headache frequency and average headache duration decreased (by 34% and 24%,
respectively). Zonisamide also decreased headache-related disability in this study, and
was well-tolerated. Krusz examined the effect of zonisamide on 33 patients who had
refractory migraine with or without tension type headache.10 The zonisamide dose range
was 100-600 mg/day. Of the 23 patients who had been evaluated, 14 had a decrease in
headache frequency of 25%-65%. Our population of patients may have been more
refractory than these. This might be due to differences in various demographic and
disease-related factors, including age, disease duration, attack frequency and severity and
co-morbidity.

Our study did not show a statistically significant beneficial effect of zonisamide on
headache or on any of the other evaluated parameters. It should be noted that our study
population consisted of refractory patients who had failed multiple migraine preventive
drugs prior to zonisamide therapy. They also had a high prevalence of depression and
anxiety, rendering their management more challenging.
The limitations of this study include a small sample size, a retrospective, open label, noncontrolled design, and variability among patients in zonisamide dosing regimen.
Additionally, study patients were taking various doses of other preventive and acute pain
medications at the time of study, potentially confounding the results.
Controlled studies are needed to evaluate the role of zonisamide in migraine prevention.
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Medication Class

Number
(%) of
Patients

Anticonvulsants (gabapentin, lamotrigine,

30 (91%)

levetiracetam, topiramate, valproic acid)
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Antidepressants (amitriptyline,

22 (66%)

nortriptyline, fluoxetine, paroxetine,
venlafaxine, mirtazapine, phenelzine)

Herbal medicines, vitamins and minerals

18 (54%)

(feverfew, riboflavin, coenzyme Q10,
magnesium)

Anti-psychotics (quetiapine, olanzapine,

16 (48%)

ziprasidone)

NSAIDs (indomethacin, celecoxib)

10 (30%)

Calcium channel blockers (verapamil,

8 (24%)

diltiazem)

Anxiolytics (buspirone)

5 (15%)
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Table: Headache preventive medications used unsuccessfully by patients prior to
zonisamide treatment
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Figure: Average number of headache days per month before and after treatment with zonisamide
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